Dr Lukasz Magiera

University of Cambridge

University departments
Cancer Research UK Cambridge Institute

Position: Research Associate
Personal home page:

PubMed journal articles - click here

Research description

A subset of tumoural cells, which is identified by expression of Fibroblast Activation Protein alpha (FAP), possess immunosuppressive properties that protect cancer cells from T cell-mediated elimination. I investigate the origin of those cells and their accumulation at the tumour site as well as their embryonic origin and novel ways of neutralising FAP cell-related immunosuppression.

Research Programme
Pancreatic Cancer
Methods and technologies
Confocal microscopy
Fluorescence microscopy
Tumour type interests

cancer stroma microenvironment immune response immunosuppression

Recent publications:
 Retrieving latest data from feed...

Symplectic Elements feed provided by Research Information, University of Cambridge

Key publications

Tumoral immune suppression by macrophages expressing fibroblast activation protein-? and heme oxygenase-1. Arnold JN, Magiera L, Kraman M, Fearon DT. Cancer Immunol Res. 2014 Feb;2(2):121-6. doi: 10.1158/2326-6066.CIR-13-0150. Epub 2013 Nov 18. PMID: 24778275 Activation of the Hippo pathway by CTLA-4 regulates the expression of Blimp-1 in the CD8+ T cell. Thaventhiran JE, Hoffmann A, Magiera L, de la Roche M, Lingel H, Brunner-Weinzierl M, Fearon DT. Proc Natl Acad Sci U S A. 2012 Aug 14;109(33):E2223-9. doi: 10.1073/pnas.1209115109. Epub 2012 Jun 27. PMID: 22745171 Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. Kraman M, Bambrough PJ, Arnold JN, Roberts EW, Magiera L, Jones JO, Gopinathan A, Tuveson DA, Fearon DT. Science. 2010 Nov 5;330(6005):827-30. doi: 10.1126/science.1195300. PMID: 21051638